Home
  • E-mailAstrid.Lunde@uib.no
  • Phone+47 55 58 61 84
  • Visitor Address
    Alrek helseklynge, blokk D, Årstadveien 17
  • Postal Address
    Postboks 7804
    5020 Bergen

biostatisstics, pharmacoepidemiology, post authorization safety studies (PASS), R

 

Academic article
  • Show author(s) (2020). Initiation of anti-osteoporotic drugs in high-risk female patients starting glucocorticoid treatment: a population study in Norway. Archives of Osteoporosis. 1-13.
  • Show author(s) (2018). The role of comorbidity on mortality after hipd fracture: A nationwide Norwegian study of 38,126 women with hip fracture matched to a general population comparison cohort. . American Journal of Epidemiology. 389-407.
  • Show author(s) (2018). The role of comorbidity on mortality after hipd fracture: A nationwide Norwegian study of 38,126 women with hip fracture matched to a general population comparison cohort. American Journal of Epidemiology. 389-407.
  • Show author(s) (2017). Thirty-five-year Trends in First-time Hospitalization for Hip Fracture, 1-year Mortality, and the Prognostic Impact of Comorbidity: A Danish Nationwide Cohort Study, 1980-2014. Epidemiology. 898-905.
  • Show author(s) (2012). Application of a Novel Hybrid Study Design to Explore Gene-Environment Interactions in Orofacial Clefts. Annals of Human Genetics. 221-236.
  • Show author(s) (2008). Fitting mixed-effects models when data are left truncated. Insurance, Mathematics & Economics. 121-133.
  • Show author(s) (2007). Genetic and environmental influences on birth weight, birth length, head circumference and gestational age using population based parent-offspring data. American Journal of Epidemiology. 734-741.
Thesis at a second degree level
  • Show author(s) (1994). Optimal reassuranse og investeringsstrategi for et forsikringsselskap under økonomisk usikkerhet.
Doctoral dissertation
  • Show author(s) (2006). Mixed-effects models with application to insurance and genetic epidemiology.

More information in national current research information system (CRIStin)

DEMAB study (osteoporosis medication)

Pregabalin study (antiepileptica in pregnancy)

Erenumab study (migraine)

Research groups